3 research outputs found
Epigenetic mechanisms of plant-derived anticancer drugs
No full textEpigenetic mechanisms are essential for normal development and maintenance of adult life. Disruption of epigenetic processes results in deregulated gene expression and leads to life-threatening diseases, in particular, cancer. Global epigenetic alterations are a hallmark of cancer. Cancer epigenetics revealed the deregulation of all components of the epigenetic machinery including DNA methylation, histone modifications, chromatin structure, and non-coding RNAs. Drugs targeting epigenetic processes, or epi-drugs, are at the forefront of drug discovery, and plant-derived compounds have shown promise. Most of the plant-derived anticancer drugs that work through epigenetic mechanisms are polyphenols; the others are alkaloids, organosulfur compounds, and terpenoids. This review focuses on the epigenetic machinery and its basis for cancer therapy, highlights plantderived anticancer drugs with epigenetic mechanisms of action, and discusses their potential use in epigenetic therapy.Abe I, 2000, BIOCHEM BIOPH RES CO, V268, P767, DOI 10.1006-bbrc.2000.2217; Adhami VM, 2003, CLIN CANCER RES, V9, P3176; Aihara H, 2004, GENE DEV, V18, P877, DOI 10.1101-gad.1184604; Ajiro K, 1996, J BIOL CHEM, V271, P13197; Akare S, 2006, INT J CANCER, V119, P2958, DOI 10.1002-ijc.22231; Akimoto T, 2001, INT J RADIAT ONCOL, V50, P195, DOI 10.1016-S0360-3016(00)01560-1; Alhosin M, 2010, BIOCHEM PHARMACOL, V79, P1251, DOI 10.1016-j.bcp.2009.12.015; Ali S, 2010, CANCER RES, V70, P3606, DOI 10.1158-0008-5472.CAN-09-4598; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073-pnas.51.5.786; AM B. Al-Amri, 2009, SHIRAZ E MED J, V10; Amin Amr, 2009, Int J Biomed Sci, V5, P1; Amin ARMR, 2009, CANCER PREV RES, V2, P538, DOI 10.1158-1940-6207.CAPR-09-0063; Andelová Hana, 2007, Acta Medica (Hradec Kralove), V50, P171; Annabi B, 2003, CANCER BIOL THER, V2, P642; [Anonymous], 1966, PROG EXP TUMOR RES, V8, P189; Arif M, 2009, J MED CHEM, V52, P267, DOI 10.1021-jm800657z; Athar M, 2007, TOXICOL APPL PHARM, V224, P274, DOI 10.1016-j.taap.2006.12.025; Azmi AS, 2005, FEBS LETT, V579, P3131, DOI 10.1016-j.febslet.2005.04.077; Selvi B Ruthrotha, 2009, Chem Biol, V16, P203, DOI 10.1016-j.chembiol.2008.12.006; Bacolla A, 1999, J BIOL CHEM, V274, P33011, DOI 10.1074-jbc.274.46.33011; Balasubramanian S, 2010, CARCINOGENESIS, V31, P496, DOI 10.1093-carcin-bgp314; Balasubramanyam K, 2004, J BIOL CHEM, V279, P33716, DOI 10.1074-jbc.M402839200; Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074-jbc.M301580200; Balunas MJ, 2005, LIFE SCI, V78, P431, DOI 10.1016-j.lfs.2005.09.012; Banerjee M, 2010, FEBS J, V277, P3437, DOI 10.1111-j.1742-4658.2010.07750.x; Mustafi SB, 2010, PLOS ONE, V5, DOI 10.1371-journal.pone.0008719; Banerjee S, 2005, CANCER RES, V65, P9064, DOI 10.1158-0008-5472.CAN-05-1330; Banerjee S, 2007, INT J CANCER, V120, P906, DOI 10.1002-ijc.22332; Barness S., 1995, J NUTR, V125, P777; Basak S, 2008, MOL CANCER THER, V7, P3195, DOI 10.1158-1535-7163.MCT-08-0617; Basile A, 1997, INT J ANTIMICROB AG, V8, P199, DOI 10.1016-S0924-8579(97)00376-2; Bayet-Robert M, 2010, CANCER BIOL THER, V9, P8; Bellarosa D, 2005, ANTICANCER RES, V25, P2119; Benbrahim-Tallaa L, 2007, ENVIRON HEALTH PERSP, V115, P1454, DOI 10.1289-ehp.10207; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038-ng1018; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038-nature05915; Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101-gad.1787609; Berletch JB, 2008, J CELL BIOCHEM, V103, P509, DOI 10.1002-jcb.21417; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016-j.cell.2007.01.033; Best JD, 2010, DRUG DISCOV TODAY, V15, P65, DOI 10.1016-j.drudis.2009.10.010; Bhat SH, 2007, TOXICOL APPL PHARM, V218, P249, DOI 10.1016-j.taap.2006.11.022; Bisht S, 2010, MOL CANCER THER, V9, P2255, DOI 10.1158-1535-7163.MCT-10-0172; Boily G, 2009, ONCOGENE, V28, P2882, DOI 10.1038-onc.2009.147; Bontempo P, 2007, INT J BIOCHEM CELL B, V39, P1902, DOI 10.1016-j.biocel.2007.05.010; Bora-Tatar G, 2009, BIOORGAN MED CHEM, V17, P5219, DOI 10.1016-j.bmc.2009.05.042; Bourguignon LYW, 2009, J BIOL CHEM, V284, P2657, DOI 10.1074-jbc.M806708200; Bradamante S, 2004, CARDIOVASC DRUG REV, V22, P169; Bradley C, 2007, CARCINOGENESIS, V28, P2184, DOI 10.1093-carcin-bgm100; Bryant CS, 2010, MOL CANCER, V9, DOI 10.1186-1476-4598-9-47; Budillon A, 2007, RECENT PAT ANTI-CANC, V2, P119; Burbee DG, 2001, J NATL CANCER I, V93, P691, DOI 10.1093-jnci-93.9.691; Burdge G., 2010, ANNU REV PSYCHOL, V61, P439; Burich RA, 2008, BJU INT, V102, P1458, DOI 10.1111-j.1464-410X.2008.07826.x; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038-5047; Candelaria M, 2007, ANN ONCOL, V18, P1529, DOI 10.1093-annonc-mdm204; Cang SD, 2009, J HEMATOL ONCOL, V2, DOI 10.1186-1756-8722-2-22; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101-gad.1273105; Chalabi N, 2007, J HISTOCHEM CYTOCHEM, V55, P877, DOI 10.1369-jhc.7A7185.2007; Chan JY, 2008, CANCER BIOL THER, V7, P1305; Chan MM, 2003, J CELL PHYSIOL, V194, P63, DOI 10.1002-jcp.10186; Chandregowda V, 2009, EUR J MED CHEM, V44, P2711, DOI 10.1016-j.ejmech.2009.01.033; Chang BS, 2007, SCIENCE, V318, P444, DOI 10.1126-science.1145801; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074-jbc.272.48.30129; Chen J., 2010, EUR J PHARM SCI; Chen Y, 2007, BASIC CLIN PHARMACOL, V101, P427, DOI 10.1111-j.1742-7843.2007.00142.x; Chendil D, 2004, ONCOGENE, V23, P1599, DOI 10.1038-sj.onc.1207284; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016-j.ccr.2004.06.023; Cheung P, 2005, MOL ENDOCRINOL, V19, P563, DOI 10.1210-me.2004-0496; Chiang PK, 1998, PHARMACOL THERAPEUT, V77, P115, DOI 10.1016-S0163-7258(97)00089-2; Chisholm K, 2004, ANTI-CANCER DRUG, V15, P889, DOI 10.1097-00001813-200410000-00010; Choi KC, 2009, CANCER RES, V69, P583, DOI 10.1158-0008-5472.CAN-08-2442; Chuang JC, 2007, PEDIATR RES, V61, p24R, DOI 10.1203-pdr.0b013e3180457684; Chuang JC, 2005, MOL CANCER THER, V4, P1515, DOI 10.1158-1535-7163.MCT-05-0172; Constantinou AI, 2005, EUR J CANCER, V41, P647, DOI 10.1016-j.ejca.2004.12.005; Cory AH, 2002, ANTICANCER RES, V22, P3805; Cory AH, 2001, ANTICANCER RES, V21, P3807; Costa FF, 2008, GENE, V410, P9, DOI 10.1016-j.gene.2007.12.008; CRICK F, 1970, NATURE, V227, P561, DOI 10.1038-227561a0; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038-nrg2634; Czyz M, 2010, BRIT J PHARMACOL, V160, P1144, DOI 10.1111-j.1476-5381.2010.00749.x; Dai J, 2005, GENE DEV, V19, P472, DOI 10.1101-gad.1267105; Dai Y, 2005, MOL CELL BIOL, V25, P5429, DOI 10.1128-MCB.25.13.5429-5444.2005; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038-sj.onc.1204469; Darwiche N, 2007, EXPERT OPIN DRUG DIS, V2, P361, DOI 10.1517-17460441.2.3.361; Das C, 2005, IUBMB LIFE, V57, P137, DOI 10.1080-15216540500090629; Dashwood RH, 2006, CARCINOGENESIS, V27, P344, DOI 10.1093-carcin-bgi253; Degner SC, 2009, J NUTR, V139, P26, DOI 10.3945-jn.108.099259; deGraffenried LA, 2004, ANN ONCOL, V15, P885, DOI 10.1093-annonc-mdh232; Dekker FJ, 2009, DRUG DISCOV TODAY, V14, P942, DOI 10.1016-j.drudis.2009.06.008; Dinant C, 2008, EPIGENET CHROMATIN, V1, DOI 10.1186-1756-8935-1-9; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083-jcb.200208091; Do Amaral CL, 2008, ARCH TOXICOL, V82, P363, DOI 10.1007-s00204-007-0262-x; Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158-1541-7786.MCR-07-0324; Doudican NA, 2010, LEUKEMIA RES, V34, P229, DOI 10.1016-j.leukres.2009.05.017; Druesne N, 2004, CARCINOGENESIS, V25, P1227, DOI 10.1093-carcin-bgh123; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128-MCB.23.9.3173-3185.2003; Du BY, 2006, CHEMOTHERAPY, V52, P23, DOI 10.1159-000090238; Duchaine T F, 2009, Curr Oncol, V16, P61; Duechler M, 2008, CANCER CHEMOTH PHARM, V61, P727, DOI 10.1007-s00280-007-0527-3; Dujic J, 2007, J INVEST DERMATOL, V127, P1992, DOI 10.1038-sj.jid.5700801; Duraj J, 2006, NEOPLASMA, V53, P384; Eddy SF, 2007, CANCER RES, V67, P9018, DOI 10.1158-0008-5472.CAN-07-1691; Egger G, 2004, NATURE, V429, P457, DOI 10.1038-nature02625; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038-sj.onc.1205651; Eliseeva ED, 2007, MOL CANCER THER, V6, P2391, DOI 10.1158-1535-7163.MCT-07-0159; Ellinger S, 2006, CURR OPIN CLIN NUTR, V9, P722, DOI 10.1097-01.mco.0000247470.64532.34; Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158-1535-7163.MCT-08-0860; El-Rayes BF, 2006, CANCER RES, V66, P10553, DOI 10.1158-0008-5472.CAN-06-2333; Esposito M, 1996, TOXICOL APPL PHARM, V140, P370, DOI 10.1006-taap.1996.0233; Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097-01.cco.0000147383.04709.10; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038-nrg2005; Fandy TE, 2009, CURR MED CHEM, V16, P2075; Fang LJ, 2010, PLANTA MED, V76, P258, DOI 10.1055-s-0029-1186083; Fang MZ, 2005, INT J ONCOL, V26, P615; Fang MZ, 2003, CANCER RES, V63, P7563; Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158-1078-0432.CCR-05-0406; Feinberg AP, 2005, CANCER CELL, V8, P267, DOI 10.1016-j.ccr.2005.09.014; Ferenc P, 2010, J PHOTOCH PHOTOBIO B, V98, P25, DOI 10.1016-j.jphotobiol.2009.10.004; Fimognari C, 2007, ANN NY ACAD SCI, V1095, P62, DOI 10.1196-annals.1397.008; Fimognari C, 2006, MUTAT RES-FUND MOL M, V601, P92, DOI 10.1016-j.mrfmmm.2006.06.001; Fini L, 2007, J NUTR, V137, P2622; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038-ng1531; FROST P, 1990, CANCER RES, V50, P4572; Fu S., 2010, CANCER, V2010; Fujiki H, 2003, MUTAT RES-FUND MOL M, V523, P119, DOI 10.1016-S0027-5107(02)00327-5; Gadea BB, 2005, MOL BIOL CELL, V16, P1305, DOI 10.1091-mbc.E04-10-0891; Ganesan A, 2009, CURR CANCER DRUG TAR, V9, P963; Ganta S, 2009, MOL PHARMACEUT, V6, P928, DOI 10.1021-mp800240j; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074-jbc.M111871200; Gao Z, 2009, ONCOL REP, V22, P1479, DOI 10.3892-or_00000590; Gao Z, 2009, ANTICANCER RES, V29, P2025; Gao Z., 2010, CURR CANC DRUG TARGE; Ghantous A, 2010, DRUG DISCOV TODAY, V15, P668, DOI 10.1016-j.drudis.2010.06.002; Gibbs A, 2009, P NATL ACAD SCI USA, V106, P16663, DOI 10.1073-pnas.0908908106; Gilbert B, 2003, CURR MED CHEM, V10, P13, DOI 10.2174-0929867033368583; Glaser KB, 2007, BIOCHEM PHARMACOL, V74, P659, DOI 10.1016-j.bcp.2007.04.007; Glei M, 2006, TOXICOL IN VITRO, V20, P295, DOI 10.1016-j.tiv.2005.08.002; Golden EB, 2009, BLOOD, V113, P5927, DOI 10.1182-blood-2008-07-171389; Goll MG, 2006, SCIENCE, V311, P395, DOI 10.1126-science.1120976; Gopal YNV, 2009, MOL CANCER THER, V8, P552, DOI 10.1158-1535-7163.MCT-08-0661; Gopal YV, 2007, CHEM BIOL, V14, P813, DOI 10.1016-j.chembiol.2007.007; Gowher H, 2001, J MOL BIOL, V309, P1201, DOI 10.1006-jmbi.2001.4710; GRAFF JR, 1995, CANCER RES, V55, P5195; Gray S. G., 2001, Current Molecular Medicine (Hilversum), V1, P401, DOI 10.2174-1566524013363537; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006-excr.2000.5080; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093-embo-reports-kvf005; Guerrero-Beltran CE, 2010, TOXICOL LETT, V192, P278, DOI 10.1016-j.toxlet.2009.11.007; Guil S, 2009, INT J BIOCHEM CELL B, V41, P87, DOI 10.1016-j.biocel.2008.09.005; Guo JY, 2004, J NUTR, V134, P179; GUO XW, 1995, EMBO J, V14, P976; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111-j.1432-1033.1978.tb12135.x; Guzman ML, 2005, EXPERT OPIN BIOL TH, V5, P1147, DOI 10.1517-14712598.5.9.1147; Guzman ML, 2007, BLOOD, V110, P4427, DOI 10.1182-blood-2007-05-090621; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073-pnas.0430973100; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146-annurev.pathol.4.110807.092250; Harikumar KB, 2010, INT J CANCER, V127, P257, DOI 10.1002-ijc.25041; Hassan YI, 2008, NUTR REV, V66, P721, DOI 10.1111-j.1753-4887.2008.00127.x; Hatcher H, 2008, CELL MOL LIFE SCI, V65, P1631, DOI 10.1007-s00018-008-7452-4; Hauser AT, 2008, PLANTA MED, V74, P1593, DOI 10.1055-s-2008-1081347; Hayashi S, 2010, INT J MOL MED, V25, P81, DOI 10.3892-ijmm_00000316; Hayashi S, 2008, INT J MOL MED, V21, P585; Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093-mutage-ge1068; Herman-Antosiewicz A, 2004, MUTAT RES-FUND MOL M, V555, P121, DOI 10.1016-j.mrfmmm.2004.04.016; Hermann RM, 2007, STRAHLENTHER ONKOL, V183, P195, DOI 10.1007-s00066-007-1561-0; Hermann RM, 2008, RADIAT ONCOL, V3, DOI 10.1186-1748-717X-3-19; Hillman GG, 2007, BMC CANCER, V7, DOI 10.1186-1471-2407-7-4; Hillman GG, 2001, CLIN CANCER RES, V7, P382; Hirsch K, 2007, BREAST CANCER RES TR, V104, P221, DOI 10.1007-s10549-006-9405-7; Ho E, 2009, J NUTR, V139, P2393, DOI 10.3945-jn.109.113332; Holcomb B, 2008, J GASTROINTEST SURG, V12, P288, DOI 10.1007-s11605-007-0406-6; Horvath Z, 2005, EXP HEMATOL, V33, P329, DOI 10.1016-j.exphem.2004.11.009; Horvath Z, 2006, NUCLEOS NUCLEOT NUCL, V25, P1019, DOI 10.1080-15257770600890574; Howells LM, 2007, INT J CANCER, V121, P175, DOI 10.1002-ijc.22645; Huang Y, 2010, PLOS ONE, V5, DOI 10.1371-journal.pone.0008888; Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073-pnas.0700720104; Hussain T, 2005, INT J CANCER, V113, P660, DOI 10.1002-ijc.20629; Hwang JT, 2007, ANN NY ACAD SCI, V1095, P441, DOI 10.1196-annals.1397.047; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038-nrm2868; Issa JPJ, 2007, CLIN CANCER RES, V13, P1634, DOI 10.1158-1078-0432.CCR-06-2076; Jagadeesh S, 2007, BIOCHEM BIOPH RES CO, V362, P212, DOI 10.1016-j.bbrc.2007.08.005; Jamison JR, 2003, CLIN GUIDE NUTR DIET; Janssenn M. J., 1967, 2 ORG SULF S HELD GR; Jawaid K, 2010, J STEROID BIOCHEM, V120, P164, DOI 10.1016-j.jsbmb.2010.04.007; Jazirehi AR, 2004, MOL CANCER THER, V3, P71; Jia D, 2007, NATURE, V449, P248, DOI 10.1038-nature06146; Jiang CZ, 2009, NAT REV GENET, V10, P161, DOI 10.1038-nrg2522; Jiang HC, 2010, CANCER SCI, V101, P975, DOI 10.1111-j.1349-7006.2009.01464.x; Jiemjit A, 2008, ONCOGENE, V27, P3615, DOI 10.1038-sj.onc.1211018; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038-nrd772; Jones P, 2006, BIOORG MED CHEM LETT, V16, P5948, DOI 10.1016-j.bmcl.2006.09.002; Jones P, 2008, CURR PHARM DESIGN, V14, P545, DOI 10.2174-138161208783885317; Jones PA, 2007, CELL, V128, P683, DOI 10.1016-j.cell.2007.01.029; JONES PA, 1985, PHARMACOL THERAPEUT, V28, P17, DOI 10.1016-0163-7258(85)90080-4; Jung HJ, 2005, BIOL PHARM BULL, V28, P101, DOI 10.1248-bpb.28.101; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073-pnas.91.25.11797; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158-0008-5472.CAN-06-1570; Kai L, 2010, INT J CANCER, V126, P1538, DOI 10.1002-ijc.24928; Kamat AM, 2009, CANCER RES, V69, P8958, DOI 10.1158-0008-5472.CAN-09-2045; Kaminski B. M., 2010, CANC CHEMOTHER PHARM; Kang HJ, 2009, BREAST J, V15, P223, DOI 10.1111-j.1524-4741.2009.00709.x; Kang JH, 2005, BIOCHEM PHARMACOL, V69, P1205, DOI 10.1016-j.bcp.2005.01.014; Kang SK, 2006, STEM CELLS DEV, V15, P165, DOI 10.1089-scd.2006.15.165; Karas M, 2000, NUTR CANCER, V36, P101, DOI 10.1207-S15327914NC3601_14; Kato K, 2008, BRIT J CANCER, V99, P647, DOI 10.1038-sj.bjc.6604521; Khafif A, 2009, LARYNGOSCOPE, V119, P2019, DOI 10.1002-lary.20582; Khoshyomn S, 2000, PEDIATR NEUROSURG, V33, P123, DOI 10.1159-000028993; Khoshyomn S, 2002, J NEURO-ONCOL, V57, P193, DOI 10.1023-A:1015765616484; Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002-ijc.23590; Kim DH, 2003, J BIOCHEM MOL BIOL, V36, P110; Kim HG, 2008, CANCER RES, V68, P2538, DOI 10.1158-0008-5472.CAN-07-6597; Kim MK, 2009, PLOS ONE, V4, DOI 10.1371-journal.pone.0004864; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038-86507; King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002-em.20363; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038-sj.onc.1201172; Kiziltepe T, 2007, MOL CANCER THER, V6, P1718, DOI 10.1158-1535-7163.MCT-07-0010; Kondo Y, 2009, YONSEI MED J, V50, P455, DOI 10.3349-ymj.2009.50.4.455; Kothapalli N, 2005, J NUTR BIOCHEM, V16, P446, DOI 10.1016-j.jnutbio.2005.03.025; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016-S0959-437X(02)00287-3; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016-j.molcel.2005.04.021; KUBO I, 1993, J AGR FOOD CHEM, V41, P1016, DOI 10.1021-jf00030a036; Kunnumakkara AB, 2007, CANCER RES, V67, P3853, DOI 10.1158-0008-5472.CAN-06-4257; Kunnumakkara AB, 2009, INT J CANCER, V125, P2187, DOI 10.1002-ijc.24593; Kunnumakkara AB, 2008, CLIN CANCER RES, V14, P2128, DOI 10.1158-1078-0432.CCR-07-4722; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126-science.1103455; Kuzmin I, 2002, CANCER RES, V62, P3498; LaBonte MJ, 2009, BMC MED GENOMICS, V2, DOI 10.1186-1755-8794-2-67; Lachner M, 2004, COLD SPRING HARB SYM, V69, P209, DOI 10.1101-sqb.2004.69.209; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242-jcs.00493; Ladygina N. G., 2005, Biomeditsinskaya Khimiya, V51, P170; Lambert J. D., 2005, AM J CLIN NUTR, V81, P284; Lamoral-Theys D, 2010, CURR MED CHEM, V17, P812; Lan J, 2010, ACTA BIOCH BIOPH SIN, V42, P243, DOI 10.1093-abbs-gmq015; Lea MA, 2002, NUTR CANCER, V43, P90, DOI 10.1207-S15327914NC431_11; Lee BH, 2005, J BIOL CHEM, V280, P40749, DOI 10.1074-jbc.M505593200; Lee JH, 2010, P NATL ACAD SCI USA, V107, P14639, DOI 10.1073-pnas.1008522107; Lee WJ, 2006, CARCINOGENESIS, V27, P269, DOI 10.1093-carcin-bgi206; Lee WJ, 2005, MOL PHARMACOL, V68, P1018, DOI 10.1124-mol.104.008367; Lee Y., 2007, BIOSCIENCE BIOTECHNO; Lee YH, 2008, J ETHNOPHARMACOL, V118, P412, DOI 10.1016-j.jep.2008.05.006; Lei WD, 1999, ANTICANCER RES, V19, P221; Leone S, 2008, MOL CARCINOGEN, V47, P587, DOI 10.1002-mc.20416; Lev-Ari S, 2007, CANCER INVEST, V25, P411, DOI 10.1080-07357900701359577; Li DH, 1999, J NUTR, V129, P1075; Li L, 2005, CANCER, V104, P1322, DOI 10.1002-cncr.21300; Li L, 2007, MOL CANCER THER, V6, P1276, DOI 10.1158-1535-7163.MCT-06-0556; Li Xin-Gang, 2006, Ai Zheng, V25, P582; Li YW, 2004, PANCREAS, V28, pE90, DOI 10.1097-00006676-200405000-00020; Li YW, 2005, CANCER RES, V65, P6934, DOI 10.1158-0008-5472.CAN-04-4604; Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002-ijc.24398; Liang G, 2002, CANCER RES, V62, P961; Liang G, 2010, INT J ONCOL, V37, P111, DOI 10.3892-ijo_00000659; Liang Y. J., 2010, AI ZHENG, V29, P9; Liang YJ, 2009, INT J GYNECOL CANCER, V19, P1248, DOI 10.1111-IGC.0b013e3181b33d76; Liao CH, 2004, BIOCHEM PHARMACOL, V67, P2031, DOI 10.1016-j.bcp.2004.02.010; Lin JN, 2010, J AGR FOOD CHEM, V58, P1584, DOI 10.1021-jf9035782; Lin XH, 2001, CANCER RES, V61, P8611; Ling X, 2009, AM J TRANSL RES, V1, P393; Liu HL, 2005, ACTA PHARMACOL SIN, V26, P603, DOI 10.1111-j.1745-7254.2005.00081.x; Liu JD, 2001, J CELL BIOCHEM, V83, P631, DOI 10.1002-jcb.1261; Liu L, 2008, CURR ISSUES MOL BIOL, V10, P25; Liu Q., 2010, ANN REV BIOCH; Liu Y, 2008, J CONTROL RELEASE, V129, P18, DOI 10.1016-j.jconrel.2008.03.022; Liu ZF, 2009, BIOORG MED CHEM LETT, V19, P706, DOI 10.1016-j.bmcl.2008.12.041; Liu ZF, 2009, J PHARMACOL EXP THER, V329, P505, DOI 10.1124-jpet.108.147934; Luo T, 2010, BREAST CANCER RES, V12, DOI 10.1186-bcr2473; Lv Bi-Hua, 2007, Zhongguo Zhong Yao Za Zhi, V32, P2051; Ma XJ, 2009, DRUGS, V69, P1911, DOI 10.2165-11315680-000000000-00000; Mai A, 2009, INT J BIOCHEM CELL B, V41, P199, DOI 10.1016-j.biocel.2008.08.020; Mai ZM, 2007, MOL CARCINOGEN, V46, P534, DOI 10.1002-mc.20300; Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093-carcin-bgp042; Majid S, 2010, CANCER, V116, P66, DOI 10.1002-cncr.24662; Majid S, 2010, CANCER RES, V70, P2809, DOI 10.1158-0008-5472.CAN-09-4176; Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158-0008-5472.CAN-07-2290; Malikova Jana, 2006, Biomedical Papers (Olomouc), V150, P5; Mandel I. D., 1994, J AM DENT ASSOC, V125, p2S; Manske R. H. F., 1965, ALKALOIDS CHEM PHYSL; Mansour A, 2007, CANCER IMMUNOL IMMUN, V56, P501, DOI 10.1007-s00262-006-0207-x; Mao Q.Q., 2010, MOL NUTR FOOD RES; Marcu MG, 2006, MED CHEM, V2, P169, DOI 10.2174-157340606776056133; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016-j.gde.2005.01.005; Marks PA, 2000, J NATL CANCER I, V92, P1210, DOI 10.1093-jnci-92.15.1210; Maruyama R, 2002, CLIN CANCER RES, V8, P514; McLaughlin N, 2006, BRAIN RES, V1071, P1, DOI 10.1016-j.brainres.2005.10.009; McNaught A. D., 1997, IUPAC COMPENDIUM CHE; Meja KK, 2008, AM J RESP CELL MOL, V39, P312, DOI 10.1165-rcmb.2008-0012OC; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038-nm0795-686; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038-nature04020; Metzger E, 2008, NAT CELL BIOL, V10, P53, DOI 10.1038-ncb1668; Meyers R. A., ENCY PHYS SCI TECHNO; Mikolajewska P, 2008, TRANSL RES, V152, P128, DOI 10.1016-j.trsl.2008.07.004; Milligan SA, 2009, CLIN CANCER RES, V15, P4885, DOI 10.1158-1078-0432.CCR-09-0109; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038-nrc1779; Mittal A, 2003, NEOPLASIA, V5, P555; Mohammad RM, 2006, CANCER, V106, P1260, DOI 10.1002-cncr.21731; Mohammad RM, 2003, MOL CANCER THER, V2, P1361; MONTI E, 1994, ANTICANCER RES, V14, P1221; Montopoli M, 2009, CELL PROLIFERAT, V42, P195, DOI 10.1111-j.1365-2184.2009.00585.x; Moriarty RM, 2007, MINI-REV MED CHEM, V7, P827; Morrissey C, 2007, INT J UROL, V14, P545, DOI 10.1111-j.1442-2042.2007.01774.x; Motohashi N, 2000, ANTICANCER RES, V20, P4323; Muller S, 2010, CURR CANCER DRUG TAR, V10, P210; Munshi A, 2009, J GENET GENOMICS, V36, P75, DOI 10.1016-S1673-8527(08)60094-6; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074-jbc.M102288200; Muroi H, 1996, J APPL BACTERIOL, V80, P387, DOI 10.1111-j.1365-2672.1996.tb03233.x; Murugan RS, 2009, ANTICANCER RES, V29, P2301; Myzak M. C., 2006, FASEB J, P05; Myzak MC, 2006, CURR DRUG TARGETS, V7, P443, DOI 10.2174-138945006776359467; Myzak MC, 2007, EXP BIOL MED, V232, P227; Myzak MC, 2006, CARCINOGENESIS, V27, P811, DOI 10.1093-carcin-bgi265; Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158-0008-5472.CAN-04-1326; Nakashima H., 2001, OCCASIONAL PAPERS, V34, P169; Nakashima K, 2002, J BIOL CHEM, V277, P49562, DOI 10.1074-jbc.M208795200; Nathan D, 2003, P NATL ACAD SCI USA, V100, P
The clinical and biological consequences of different FLT3 mutations in patients with AML
No full textCharacterisation of pathogenic markers in acute myeloid leukaemia (AML) may benefit
patients through refinement of risk stratification, application of molecularly targeted
therapy and improved understanding of AML biology. Whilst the presence of an
internal tandem duplication (ITD) within the fms-like tyrosine kinase-3 (FLT3) gene is
known to predict adverse outcome in young adults with AML, the clinical significance
of activating mutations in the tyrosine kinase domain (TKD) of FLT3 is unclear.
Therefore, a highly sensitive and specific denaturing-HPLC technique was developed to
screen for FLT3/TKDs in 1339 young adult patients with AML. Mutations were
detected in 161 (12%) cases, with a high incidence in patients with inv(16) (24%;
P=.009), a group in which FLT3/ITDs are uncommon. Unlike FLT3/ITDs, FLT3/TKDs
were associated with a favourable long-term outcome with a 10-year overall survival
(OS) of 36% for FLT3 WT, 51% for FLT3/ITD-TKD+ and 24% for FLT3/ITD+TKDpatients
(P<.001). The relative FLT3/TKD mutant level was highly variable with the
favourable prognosis residing in those patients with greater than 25% mutant alleles
(10-year OS of 59%), possibly reflecting the stage at which the mutation is acquired.
The mechanism of FLT3 activation also influenced sensitivity to FLT3-inhibitor
induced cytotoxicity, with FLT3/ITD+ blast cells more sensitive than FLT3/TKD+ cells.
Following lentiviral transduction, FLT3/ITD-transduced 32Dcl3 and Ba/F3 cells
demonstrated more rapid proliferation than FLT3/TKD-transduced cells. In an NB4 cell
line model of ATRA-induced myeloid differentiation, the presence of a FLT3/ITD
inhibited differentiation unlike a FLT3/TKD mutation which increased differentiation.
Furthermore, FLT3/ITD-transduced CD34 positive haematopoietic stem cells showed
greater cytokine-free survival of colony forming cells than FLT3/TKD-transduced cells.
Signalling studies also revealed that a FLT3/ITD induced stronger STAT5 activation
than a FLT3/TKD mutation. This unexpected genotype-phenotype relationship is of
direct relevance to current clinical decision making in AML, and may also provide
insights into mechanisms of chemoresistance
The management of complicated colorectal cancer in older patients in a global perspective after COVID-19: the CO-OLDER WSES project
No full textBACKGROUND: Colorectal (CRC) cancer is becoming a disease of the elderly. Ageing is the most significant risk factor for presenting CRC. Early diagnosis of CRC and management is the best way in achieving good outcomes and longer survival but patients aged ≥75 years are usually not screened for CRC. This group of patients is often required to be managed when they are symptomatic in the emergency setting with high morbidity and mortality rates. Our main aim is to provide clinical data about the management of elderly patients presenting complicated colorectal cancer who required emergency surgical management to improve their care. METHODS: The management of complicated COlorectal cancer in OLDER patients (CO-OLDER; ClinicalTrials.gov ID: NCT05788224; evaluated by the local ethical committee CPP EST III-France with the national number 2023-A01094-41) in the emergency setting project provides carrying out an observational multicenter international cohort study aimed to collect data about patients aged ≥75 years to assess modifiable risk factors for negative outcomes and mortality correlated to the emergency surgical management of this group of patients at risk admitted with a complicated (obstructed and perforated) CRC. The CO-OLDER protocol was approved by Institutional Review Board and released. Each CO-OLDER collaborator is asked to enroll ≥25 patients over a study period from 1st January 2018 to 30th October 2023. Data will be analyzed comparing two periods of study: before and after the COVID-19 pandemic. A sample size of 240 prospectively enrolled patients with obstructed colorectal cancer in a 5-month period was calculated. The secured database for entering anonymized data will be available for the period necessary to achieve the highest possible participation. RESULTS: One hundred eighty hospitals asked to be a CO-OLDER collaborator, with 36 potentially involved countries over the world. CONCLUSIONS: The CO-OLDER project aims to improve the management of elderly people presenting with a complicated colorectal cancer in the emergency setting. Our observational global study can provide valuable data on the effectiveness of different management strategies in improving primary assessment, management and outcomes for elderly patients with obstructed or perforated colorectal cancer in the emergency setting, guiding clinical decision-making. This information can help healthcare providers make informed decisions about the best course of action for these patients
